Reuters Health Report: September 1, 2017

Click to View in Browser Friday, September 1, 2017 Advertising budget for Obamacare to be cut 90 percent: U.S. health agency WASHINGTON (Reuters) - The U.S. Centers for Medicare and Medicaid Services said on Thursday it plans to spend $10 million on advertising for the upcoming Obamacare open enrollment period that starts in November, a sharp cut from the $100 million spent last year. Arizona accuses drugmaker Insys of fraudulent opioid marketing (Reuters) - Arizona sued Insys Therapeutics Inc on Thursday, accusing the drugmaker of engaging in a fraudulent marketing scheme aimed at increasing sales of a fentanyl-based cancer pain medicine called Subsys. Amazon hit with lawsuit over eclipse glasses NEW YORK (Reuters) - Amazon.com has been hit with a proposed class action lawsuit by a couple who claims defective eclipse glasses purchased through the online retailer damaged their eyes. AstraZeneca aims to offset drug setback at big cancer congress LONDON (Reuters) - After last month's big clinical trial setback in lung cancer, AstraZeneca will seek to rebuild its oncology reputation next week when it unveils full details of two key clinical trials tackling the disease in different ways. Most physical therapists face sexual harassment from patients (Reuters Health) - Inappropriate patient sexual behavior remains a common experience for physical therapists during their careers, according to a recent U.S. study. Quick 'mindfulness' fix may help curb drinking (Reuters Health) - Heavy drinkers may be able to cut back after brief mindfulness training exercises that involve helping them focus on what's happening in the present moment, a small experiment in the UK suggests. Profit on $475,000 Novartis cancer drug could be a while coming ZURICH (Reuters) - Novartis's new gene-modifying cancer therapy's $475,000-per-patient sticker price has drawn fire from advocate groups calling for cheaper drugs, but analysts said the Swiss drugmaker could initially struggle to break even. Britain 'going backwards' on rights of disabled, says U.N. committee GENEVA (Reuters) - The U.N. Committee on the rights of disabled people said on Thursday it had more concerns about Britain - due to funding cuts, restricted rights and an uncertain post-Brexit future - than any other country in its 10-year history. Novartis gene therapy approval signals new cancer treatment era (Reuters) - Novartis AG on Wednesday won highly anticipated U.S. approval for the first of a new type of potent gene-modifying immunotherapy for leukemia, a $475,000 treatment that marks the start of a potential new treatment paradigm for some cancers. Japan's Daiichi Sankyo denies 2016 takeover bid by AstraZeneca TOKYO (Reuters) - Japanese drugmaker Daiichi Sankyo denied on Thursday it received a takeover bid last year from Britain's AstraZeneca, following speculation that sent its share price soaring as much as 13 percent and triggered a trade suspension. Related Video Landfill turned park proves nature's resilience Low-cost sanitary towels made from sugarcane by-products A quick-fix on the day's news delivered when you want it. Register Today A daily digest of breaking business news, coverage of the US economy, major corporate news and the financial markets. Register Today » » MORE NEWSLETTERS - 3 Times Square New York, NY 10036 USA © Copyright 2017 Thomson Reuters Ensure delivery of Reuters Newsmails, add newsletters@email.reuters.com to your address book. Subscribe to other Reuters newsletters. Unsubscribe from this newsletter. Follow us on Twitter Friend us on Facebook